FUSN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FUSN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Fusion Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2023 was $-376.76 Mil.
Fusion Pharmaceuticals's quarterly retained earnings declined from Jun. 2023 ($-331.33 Mil) to Sep. 2023 ($-348.58 Mil) and declined from Sep. 2023 ($-348.58 Mil) to Dec. 2023 ($-376.76 Mil).
Fusion Pharmaceuticals's annual retained earnings declined from Dec. 2021 ($-194.25 Mil) to Dec. 2022 ($-281.86 Mil) and declined from Dec. 2022 ($-281.86 Mil) to Dec. 2023 ($-376.76 Mil).
The historical data trend for Fusion Pharmaceuticals's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Retained Earnings | Get a 7-Day Free Trial | -34.77 | -113.20 | -194.25 | -281.86 | -376.76 |
Fusion Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Retained Earnings | Get a 7-Day Free Trial | -281.86 | -306.15 | -331.33 | -348.58 | -376.76 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Fusion Pharmaceuticals (NAS:FUSN) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Teresa Marie Bitetti | director | 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Jeremy Bender | director | 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
David D. Meek | director | 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906 |
Dmitri Bobilev | officer: Chief Medical Officer | C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6 |
Steven Gannon | director | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8 |
John Valliant | director, officer: Chief Executive Officer | FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6 |
Christopher P Leamon | officer: Chief Scientific Officer | C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110 |
Mohit Rawat | officer: President and CBO | FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6 |
Donald A Bergstrom | director | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Philina Lee | director | C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6 |
Adams Street Partners Llc | 10 percent owner | ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
John J Crowley | officer: Chief Financial Officer | 251 BALLARDVALE STREET, WILMINGTON MA 01887 |
Healthcap Vii, L.p. | 10 percent owner | 18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018 |
James J O'leary | officer: Chief Medical Officer | 830 WINTER STREET, WALTHAM MA 02452 |
From GuruFocus
By PRNewswire • 01-04-2024
By PRNewswire PRNewswire • 02-14-2023
By PRNewswire • 12-11-2023
By PRNewswire PRNewswire • 02-13-2023
By PRNewswire • 10-16-2023
By PRNewswire • 12-08-2023
By PRNewswire PRNewswire • 05-02-2023
By PRNewswire • 09-13-2023
By PRNewswire • 11-14-2023
By PRNewswire • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.